Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation develops and commercializes ophthalmic pharmaceutical and medical technology products for glaucoma, corneal disorders, and retinal diseases. News about Glaukos regularly covers financial results, global commercial execution, and updates for its dropless platform technologies, including iDose TR for sustained intracameral glaucoma drug delivery and Epioxa for corneal cross-linking in keratoconus.
Recurring company developments include FDA labeling actions for iDose TR, CMS coding and commercial availability updates for Epioxa, scientific presentations in ophthalmology, and quarterly sales trends across its glaucoma franchise. Company background also includes Micro-Invasive Glaucoma Surgery products such as iStent, iStent inject W, and iStent infinite, along with a pipeline aimed at chronic eye diseases.
Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, has broken ground on a new 200,000 square-foot research, development, and manufacturing facility in Huntsville, Alabama. The project represents a planned investment of over $80 million and is expected to create more than 150 full-time jobs in the region.
The company selected Huntsville from over 100 potential sites worldwide, citing the area's strong talent base and vibrant business climate. Located in Cummings Research Park, the facility will be built on 25 acres with an option for an additional 15 acres for future expansion. The project is scheduled for completion by 2030 and aims to strengthen U.S. manufacturing capabilities while supporting Glaukos' long-term growth plans.
Glaukos Corporation (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology solutions for glaucoma, corneal disorders, and retinal diseases, has announced its upcoming participation in the Wells Fargo Healthcare Conference.
The presentation is scheduled for September 3, 2025, at 10:15 a.m. ET in Boston, MA. Investors can access both live and archived webcasts of the event through the Investors section of Glaukos's website at investors.glaukos.com.
Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, reported strong Q2 2025 financial results with record net sales of $124.1 million, marking a 30% year-over-year increase. The company's Glaucoma segment achieved record sales of $103.5 million, up 36% year-over-year, with U.S. Glaucoma sales reaching $72.3 million, a 45% increase.
Key financial metrics include a gross margin of 78% (83% non-GAAP), though the company reported a net loss of $19.7 million ($0.34 per share). The company maintains a strong financial position with $278.6 million in cash and investments with no debt. Based on strong performance, Glaukos raised its 2025 net sales guidance to $480-486 million from the previous $475-485 million range.
[ "Record net sales of $124.1M, up 30% year-over-year", "Strong Glaucoma segment growth with 36% YoY increase to $103.5M", "U.S. Glaucoma sales up 45% YoY to $72.3M", "Improved gross margin to 78% (83% non-GAAP)", "Raised 2025 revenue guidance to $480-486M", "Strong balance sheet with $278.6M cash and no debt" ]Glaukos Corporation (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology, has scheduled the release of its second quarter 2025 financial results after market close on Wednesday, July 30, 2025.
The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Investors can access the live webcast through the company's investor relations website, or join via phone using the provided dial-in numbers and Conference ID 5255602.
Glaukos (NYSE: GKOS) has received European Union Medical Device Regulation (MDR) certification for its iStent infinite® and iStent inject® W micro-invasive glaucoma surgery (MIGS) technologies. These are the company's first approvals under the new EU regulatory framework.
The iStent® platform involves micro-scale surgical devices that reduce intraocular pressure by restoring natural aqueous humor outflow pathways in glaucoma patients. The company's MIGS technologies are supported by nearly 400 peer-reviewed publications and have achieved over one million implants worldwide.
Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, will celebrate its 10th IPO anniversary by ringing the NYSE Closing Bell on June 25, 2025. CEO Thomas Burns highlighted the company's transformation from a single-product, U.S.-focused entity to a global ophthalmology leader with over 1,000 employees.
The ceremonial event marks a decade of growth in developing therapies for glaucoma, corneal disorders, and retinal diseases. The closing bell ceremony will be live-streamed on the NYSE website and may be broadcast on various media outlets including CNBC.
Glaukos Corporation (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology for glaucoma, corneal disorders, and retinal diseases, has announced its upcoming participation in three major investor conferences:
- Stifel 2025 Virtual Ophthalmology Forum on May 27, 2025, at 12:30 p.m. ET
- William Blair 45th Annual Growth Stock Conference on June 3, 2025, at 1:40 p.m. ET in Chicago
- Jefferies Global Healthcare Conference on June 4, 2025, at 8:45 a.m. ET in New York City
Live and archived webcasts of these events will be accessible through the Investors section of Glaukos's website.
Glaukos reported strong Q1 2025 financial results with record net sales of $106.7 million, marking a 25% year-over-year increase. The company's Glaucoma segment achieved record sales of $88.1 million, up 31% from the previous year, with U.S. Glaucoma sales reaching $59.1 million, a 41% increase.
Key financial metrics include:
- Gross margin of 77% (82% non-GAAP)
- Operating loss reduced to $20.7 million from $39.1 million year-over-year
- Net loss improved to $18.1 million ($0.32 per share) from $40.8 million ($0.82 per share)
The company maintains a strong financial position with $303.4 million in cash and investments, carrying no debt. Glaukos reaffirmed its 2025 net sales guidance of $475-485 million, demonstrating confidence in continued growth. The company's focus remains on developing novel, dropless platform technologies for chronic eye diseases.
Glaukos (NYSE: GKOS) has announced its participation in the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting from April 25-28 in Los Angeles. The company will showcase its technologies at booth #2227 and sponsor an educational symposium on 'Empowering Interventional Glaucoma Care.'
The scientific program features several key presentations including:
- 10-year glaucoma control outcomes with trabecular micro-bypass
- 12-month results of third-generation trabecular micro-bypass stent
- 36-month outcomes of travoprost intracameral implant
- Studies on corneal collagen cross-linking for keratoconus
Notable speakers include Dr. Fritz Hengerer, Dr. Zachary Vest, Dr. Inder Singh, and Dr. Vance Thompson, presenting research on glaucoma control, medication reduction, and corneal health treatments.
Glaukos (NYSE: GKOS) has released its sixth annual Sustainability Report for 2024, showcasing significant progress in corporate sustainability initiatives. The ophthalmic pharmaceutical and medical technology company reported several key achievements:
- Donated approximately $7 million in products globally, reaching a total of over $17 million in donations to date
- Conducted 45 philanthropic volunteer events with 25 nonprofit organizations, accumulating over 700 volunteer hours
- Expanded patient services program to nearly 5,000 keratoconus patients, totaling 8,000 patients since 2023
- Implemented a two-site distribution model reducing 20 million air miles and 4,000 tons of greenhouse emissions
- Launched the iDose Your Dose initiative, matching each iDose® TR unit sold with a donation to charitable requests
The company also announced plans for a new research facility in Huntsville, Alabama, and introduced enhanced employee benefits including mental health support and student loan repayment programs.